<DOC>
	<DOCNO>NCT00903968</DOCNO>
	<brief_summary>The purpose research study determine safety plerixafor bortezomib , high dose give people safely . Plerixafor appear stop myeloma cell attach bone marrow use phase I study mobilization stem cell patient myeloma lymphoma . We show combination plerixafor bortezomib effective kill myeloma cell laboratory effect drug alone .</brief_summary>
	<brief_title>Combination Plerixafor ( AMD3100 ) Bortezomib Relapsed Relapsed/Refractory Multiple Myeloma</brief_title>
	<detailed_description>- Since look high dos combine study drug administer safely without severe unmanageable side effect participant multiple myeloma everyone participates receive dose study drug . The dose participant receive depend number participant study tolerated dos . - Plerixafor give injection skin day 1 , 2 , 4 5 . Participants receive plerixafor bortezomib day 3 6 bortezomib alone day 10 13 . Bortezomib administer intravenously . Each treatment cycle last 21 day . - The cycle repeat 8 cycle long participant severe unmanageable side effect disease respond study drug . - While receive study drug start study cycle , participant come clinic follow perform : physical exam , question current health current medication , blood work , urine sample , x-rays ( deemed necessary ) EKG .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>JM 3100</mesh_term>
	<criteria>18 year age old Must receive prior 15 therapy myeloma relapsed refractory multiple myeloma . Prior therapy bortezomib allow long refractory bortezomib Monoclonal protein serum 1gm/dL great monoclonal light chain urine protein electrophoresis 200 mg/24 hour great , measurable light chain free light chain assay 10 mg/dL great , measurable plasmacytoma ECOG Performance Status 0 , 1 , 2 Laboratory value outline protocol Uncontrolled infection Cytotoxic chemotherapy &lt; 3 week , biologic target novel therapy &lt; 2 week , corticosteroid &lt; 2 week prior registration . Patients may receive chronic corticosteroid give disorder myeloma Pregnant woman Nursing woman Men woman childbearing potential unwilling employ adequate contraception Other concurrent chemotherapy , immunotherapy , radiotherapy , ancillary therapy consider investigational Known HIV positive Radiation therapy &lt; 2 week prior registration</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>refractory</keyword>
	<keyword>relapse</keyword>
	<keyword>bortezomib</keyword>
	<keyword>AMD3100</keyword>
	<keyword>plerixafor</keyword>
</DOC>